Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(163)
•••
Post by Sniper007on Sep 23, 2013 4:27pm
271 Views
Post# 21761047

ratings

ratings
Hey guys,
I just wanted to mention I've been noticing some good posts being downgraded to the lowest rating of 1 star. This has been going on for at least a couple of months.  It's like someone is sabotaging the ratings.  I thought Sir_Holler's post this morning about Paul Lockman presenting at the conference was VERY useful and credible and at a very minimum was a rating of 2 stars.  I posted a rating of 5 for all and the ratings stayed at 1 star.  I'm partially at fault for not rating posts more often but I think it would be good if we all started rating good posts again. 
Having Paul Lockman present the BT2111 results at the conference is great news!  If the results were bad or inconclusive etc. he wouldn't be wasting anyone's time presenting it.  I'm assuming he will be talking about both the Feb. 7, 2013 results as well as the most recent results that we have not yet seen.  This is potentially huge!
Sniper
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities